These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Strategic development of the conserved region of the M protein and other candidates as vaccines to prevent infection with group A streptococci. Good MF, Pandey M, Batzloff MR, Tyrrell GJ. Expert Rev Vaccines; 2015; 14(11):1459-70. PubMed ID: 26485214 [Abstract] [Full Text] [Related]
3. Protection of mice from group A streptococcal infection by intranasal immunisation with a peptide vaccine that contains a conserved M protein B cell epitope and lacks a T cell autoepitope. Olive C, Clair T, Yarwood P, Good MF. Vaccine; 2002 Jun 21; 20(21-22):2816-25. PubMed ID: 12034109 [Abstract] [Full Text] [Related]
7. Molecular biology of Group A Streptococcus and its implications in vaccine strategies. Brahmadathan NK. Indian J Med Microbiol; 2017 Jun 21; 35(2):176-183. PubMed ID: 28681803 [Abstract] [Full Text] [Related]
8. Prime-Pull Immunization with a Bivalent M-Protein and Spy-CEP Peptide Vaccine Adjuvanted with CAF®01 Liposomes Induces Both Mucosal and Peripheral Protection from covR/S Mutant Streptococcus pyogenes. Ozberk V, Reynolds S, Huo Y, Calcutt A, Eskandari S, Dooley J, Mills JL, Rasmussen IS, Dietrich J, Pandey M, Good MF. mBio; 2021 Feb 23; 12(1):. PubMed ID: 33622722 [Abstract] [Full Text] [Related]
12. Protective immunity induced by an intranasal multivalent vaccine comprising 10 Lactococcus lactis strains expressing highly prevalent M-protein antigens derived from Group A Streptococcus. Wozniak A, Scioscia N, García PC, Dale JB, Paillavil BA, Legarraga P, Salazar-Echegarai FJ, Bueno SM, Kalergis AM. Microbiol Immunol; 2018 Jun 23; 62(6):395-404. PubMed ID: 29704396 [Abstract] [Full Text] [Related]
13. The emm-type diversity does not always reflect the M protein genetic diversity--is there a case for designer vaccine against GAS. Smeesters PR, Dramaix M, Van Melderen L. Vaccine; 2010 Jan 22; 28(4):883-5. PubMed ID: 19963033 [No Abstract] [Full Text] [Related]
17. Lipid core peptide technology and group A streptococcal vaccine delivery. Olive C, Batzloff MR, Toth I. Expert Rev Vaccines; 2004 Feb 22; 3(1):43-58. PubMed ID: 14761243 [Abstract] [Full Text] [Related]
18. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus. Tsoi SK, Smeesters PR, Frost HR, Licciardi P, Steer AC. J Immunol Res; 2015 Feb 22; 2015():167089. PubMed ID: 26101780 [Abstract] [Full Text] [Related]
19. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines? Smeesters PR, McMillan DJ, Sriprakash KS, Georgousakis MM. Expert Rev Vaccines; 2009 Dec 22; 8(12):1705-20. PubMed ID: 19905872 [Abstract] [Full Text] [Related]
20. Intranasal administration is an effective mucosal vaccine delivery route for self-adjuvanting lipid core peptides targeting the group A streptococcal M protein. Olive C, Sun HK, Ho MF, Dyer J, Horváth A, Toth I, Good MF. J Infect Dis; 2006 Aug 01; 194(3):316-24. PubMed ID: 16826479 [Abstract] [Full Text] [Related] Page: [Next] [New Search]